| Not Yet Recruiting | Safety, Immunogenicity, and Efficacy of Therapeutic Mycobacterium Bovis BCG (BOOST) NCT07094711 | University of Virginia | Phase 2 |
| Recruiting | Drug Exposure and Minimum Inhibitory Concentration in the Treatment of MAC Lung Disease NCT05824988 | Shanghai Pulmonary Hospital, Shanghai, China | — |
| Completed | Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection NCT00111397 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials NCT00021567 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Subcutaneously Administered Interleukin-12 Therapy in HIV-Infected Patients With Disseminated Mycobacterium Av NCT00001763 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Incre NCT00000883 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease NCT00004689 | National Jewish Health | Phase 2 |
| Completed | A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients NCT00000947 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobact NCT00002122 | Pfizer | Phase 3 |
| Completed | A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection NCT00000895 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) NCT00000644 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobact NCT00002192 | Anderson Clinical Research | Phase 2 |
| Completed | Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 NCT00002032 | Pharmacia | N/A |
| Completed | The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacte NCT00001030 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen NCT00002101 | Pharmacia | Phase 3 |
| Completed | A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Dis NCT00000641 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacte NCT00000971 | Abbott | Phase 1 |
| Completed | A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DM NCT00000907 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 NCT00002267 | Pharmacia | N/A |
| Completed | A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in NCT00002058 | University of California, San Francisco | N/A |
| Completed | The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients NCT00000860 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patient NCT00002309 | Pfizer | N/A |
| Completed | Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacteriu NCT00002104 | Aaron Diamond AIDS Research Center | Phase 1 |
| Completed | The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patie NCT00001023 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Completed | An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-I NCT00002089 | Pfizer | N/A |
| Completed | Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 04 NCT00000933 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in HIV Positive Patients NCT00002080 | Pharmacia | N/A |
| Completed | A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bac NCT00002343 | Pharmacia | Phase 4 |
| Completed | A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethamb NCT00002140 | Pfizer | Phase 3 |
| Completed | An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobact NCT00002090 | Pfizer | N/A |
| Completed | A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC) NCT00002170 | Agouron Pharmaceuticals | Phase 2 |
| Completed | A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Comple NCT00001995 | Pharmacia | N/A |
| Completed | Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) P NCT00001047 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 |
| Completed | A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Comp NCT00001058 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Av NCT00002037 | Amgen | N/A |
| Completed | A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous NCT00002085 | Pfizer | N/A |
| Completed | Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients NCT00001039 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |